Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers.

IF 2.4 3区 医学 Q3 ONCOLOGY
Atsushi Yamada, Yukari Doi, Sachiko Minamiguchi, Tomohiro Kondo, Tomohiko Sunami, Takahiro Horimatsu, Junzo Hamanishi, Masaki Mandai, Etsuro Hatano, Takashi Kobayashi, Shigeo Hisamori, Kazutaka Obama, Hiroshi Seno, Hironori Haga, Masako Torishima, Hiromi Murakami, Takeshi Nakajima, Takahiro Yamada, Shinji Kosugi, Kokichi Sugano, Manabu Muto
{"title":"Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers.","authors":"Atsushi Yamada, Yukari Doi, Sachiko Minamiguchi, Tomohiro Kondo, Tomohiko Sunami, Takahiro Horimatsu, Junzo Hamanishi, Masaki Mandai, Etsuro Hatano, Takashi Kobayashi, Shigeo Hisamori, Kazutaka Obama, Hiroshi Seno, Hironori Haga, Masako Torishima, Hiromi Murakami, Takeshi Nakajima, Takahiro Yamada, Shinji Kosugi, Kokichi Sugano, Manabu Muto","doi":"10.1007/s10147-024-02609-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic germline variants in mismatch repair (MMR) genes, which predisposes to various types of cancers showing deficient MMR (dMMR). Identification of LS probands is crucial to reduce cancer-related deaths in affected families. Although universal screening is recommended for colorectal and endometrial cancers, and age-restricted screening is proposed as an alternative, LS screening covering a broader spectrum of cancer types is needed. In the current study, we elucidated the rate of dMMR tumors and evaluated the outcome of LS screening in young-onset extra-colorectal LS-associated cancers.</p><p><strong>Methods: </strong>Immunohistochemistry for MMR proteins were retrospectively performed in a total of 309 tissue samples of endometrial, non-mucinous ovarian, gastric, urothelial, pancreatic, biliary tract, and adrenal cancers in patients < 50 years of age. Clinicopathological information and the results of genetic testing were obtained from medical charts.</p><p><strong>Results: </strong>There were 24 dMMR tumors (7.8%) including 18 endometrial, three ovarian, two urothelial, and one gastric cancer. Co-occurrence of colorectal cancer and family history of LS-associated cancers was significantly enriched in patients with dMMR tumors. Among the 16 patients with dMMR tumors who were informed of the immunohistochemistry results, five with endometrial and one with urothelial cancer were diagnosed as LS with positive pathogenic variants in MMR genes.</p><p><strong>Conclusions: </strong>We report the outcome of immunohistochemistry for MMR proteins performed in multiple types of young-onset extra-colorectal LS-associated cancers. Our study demonstrates the feasibility of a comprehensive LS screening program incorporating young-onset patients with various types of extra-colorectal LS-associated cancers.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1696-1703"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02609-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic germline variants in mismatch repair (MMR) genes, which predisposes to various types of cancers showing deficient MMR (dMMR). Identification of LS probands is crucial to reduce cancer-related deaths in affected families. Although universal screening is recommended for colorectal and endometrial cancers, and age-restricted screening is proposed as an alternative, LS screening covering a broader spectrum of cancer types is needed. In the current study, we elucidated the rate of dMMR tumors and evaluated the outcome of LS screening in young-onset extra-colorectal LS-associated cancers.

Methods: Immunohistochemistry for MMR proteins were retrospectively performed in a total of 309 tissue samples of endometrial, non-mucinous ovarian, gastric, urothelial, pancreatic, biliary tract, and adrenal cancers in patients < 50 years of age. Clinicopathological information and the results of genetic testing were obtained from medical charts.

Results: There were 24 dMMR tumors (7.8%) including 18 endometrial, three ovarian, two urothelial, and one gastric cancer. Co-occurrence of colorectal cancer and family history of LS-associated cancers was significantly enriched in patients with dMMR tumors. Among the 16 patients with dMMR tumors who were informed of the immunohistochemistry results, five with endometrial and one with urothelial cancer were diagnosed as LS with positive pathogenic variants in MMR genes.

Conclusions: We report the outcome of immunohistochemistry for MMR proteins performed in multiple types of young-onset extra-colorectal LS-associated cancers. Our study demonstrates the feasibility of a comprehensive LS screening program incorporating young-onset patients with various types of extra-colorectal LS-associated cancers.

Abstract Image

对年轻的结直肠外林奇综合征相关癌症患者进行林奇综合征筛查。
背景:林奇综合征(Lynch Syndrome,LS)是一种遗传性癌症综合征,由错配修复(MMR)基因的致病性种系变异引起,易患MMR缺陷(dMMR)的各种癌症。要减少受影响家庭中与癌症相关的死亡,识别 LS 疑似者至关重要。尽管建议对结直肠癌和子宫内膜癌进行普遍筛查,并提出了限制年龄的筛查作为替代方案,但仍需要对更广泛的癌症类型进行 LS 筛查。在本研究中,我们阐明了dMMR肿瘤的发病率,并评估了年轻发病的结直肠外LS相关癌症的LS筛查结果:方法:对309例子宫内膜癌、非黏液性卵巢癌、胃癌、尿道癌、胰腺癌、胆道癌和肾上腺癌患者的组织样本进行MMR蛋白免疫组化:共有 24 例 dMMR 肿瘤(7.8%),包括 18 例子宫内膜癌、3 例卵巢癌、2 例尿路上皮癌和 1 例胃癌。在患有dMMR肿瘤的患者中,结直肠癌和LS相关癌症家族史的并发率明显增高。在获知免疫组化结果的16名dMMR肿瘤患者中,5名子宫内膜癌患者和1名尿道癌患者被诊断为LS,且MMR基因存在阳性致病变异:我们报告了在多种年轻发病的结直肠外LS相关癌症中进行MMR蛋白免疫组化的结果。我们的研究表明,将患有各种类型结直肠外LS相关癌症的年轻患者纳入LS综合筛查计划是可行的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信